(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) rose by a staggering 31.87% in 5 sessions from €0.09 to €0.12 at 05:11 EST on Tuesday, following the last session’s upward trend. BEL 20 is jumping 0.16% to €3,805.96, after two successive sessions in a row of gains.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.38.
Volume
Today’s last reported volume for BIOSENIC is 144516 which is 82.01% below its average volume of 325829.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC’s stock is considered to be oversold (<=20).
Volatility
BIOSENIC’s last week, last month’s, and last quarter’s current intraday variation average was a positive 6.85%, a negative 1.94%, and a positive 6.03%.
BIOSENIC’s highest amplitude of average volatility was 6.99% (last week), 4.80% (last month), and 6.03% (last quarter).
More news about BIOSENIC (BIOS.BR).
